Edgeworth Client Receives Settlement Resolving Patent and Antitrust Litigation
In May 2019, Edgeworth client Amphastar Pharmaceuticals Inc. obtained a settlement valued at about $60 million, thereby resolving both a patent litigation brought by two competitor pharmaceutical companies and Amphastar’s antitrust countersuit. The patent related to a method for testing enoxaparin, a blockbuster blood-thinning drug.
Edgeworth President Dr. Jesse David testified at trial on damages and further provided post-trial opinions regarding harm to Amphastar due to an earlier preliminary injunction in the same matter. Dr. David provided additional expert opinions in the countersuit brought by Amphastar, alleging antitrust violations.